生物標識：市場動向

Abstract

This market insight report on Biomarkers focuses on the different types of biomarkers and their impact on various disease areas such as oncology, neurology, cardiology and other areas including metabolomic turmoil, arthritis, gynecology, oxidative stress, liver disease, pulmonary disease and aging. The study provides global market analysis for biomarkers by the above disease areas and also by prominent biomarker discovery technologies including imaging, genomics, proteomics, metabolomics, bioinformatics and other technologies comprising fluorescent indicators, lab-on-chip, nuclear magnetic resonance, mass spectrometry/liquid chromatography and nanobiotechnology. Though the report mentions about non-medical applications of biomarkers, the study emphasizes only on the medical applications. The study includes estimates and projections for the total global biomarkers market. The market covered for genomics, proteomics and bioinformatics pertains only to biomarker discovery applications. Projections and estimates figure for geographic regions including United States, Europe, Japan, Asia-Pacific, Canada and Rest of World. The industry is analyzed in US Dollars and includes 199 exclusive exhibits. A total of 402 companies are covered that are engaged in biomarkers R&D, discovery, testing, and supply of products and services.

Table of Contents

I. SCOPE AND METHODOLOGY

II. REPORT SYNOPSIS

• 1. Introduction
  • Biomarkers
  • Segmentation of Biomarkers
    • Exhibit 1: Segmentation of Global Biomarkers Market By Discovery Technology (Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other) and Therapeutic Area (Oncology, Cardiology, Neurology and Other)
• 2. Global Market Analysis
  • Exhibit 2: Biomarkers (2005-2012) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  • Therapeutic Area Analysis by Geographic Region
    • Oncology
      • Exhibit 3: Biomarkers in Oncology (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 4: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
    • Cardiology
      • Exhibit 5: Biomarkers in Cardiology (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 6: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
    • Neurology
      • Exhibit 7: Biomarkers in Neurology (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 8: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
    • Other
      • Exhibit 9: Biomarkers in Other Therapeutics (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 10: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
  • Biomarker Discovery Technology Analysis by Geographic Region
    • Imaging
      • Exhibit 11: Imaging Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 12: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
    • Genomics
      • Exhibit 13: Genomic Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million(Graphical Representation Included)
      • Exhibit 14: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World(Graphical Representation Included)
    • Proteomics
      • Exhibit 15: Proteomic Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 16: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
    • Metabolomics
      • Exhibit 17: Metabolomic Technologies for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 18: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
    • Bioinformatics
      • Exhibit 19: Bioinformatics for Biomarker Discovery (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 20: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
    • Other
      • Exhibit 21: Other Biomarker Discovery Technologies (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 22: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Exhibit 23: List of Major Global Companies
• 2. Regional Market Analysis
  • North America
    • Exhibit 24: Biomarkers (2005-2012) - North American Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  • Major Companies in North America
    • Affymetrix, Inc. (USA)
    • Agilent Technologies, Inc. (USA)
    • Applied Biosystems Group (USA)
    • AVIVA Biosciences Corporation (USA)
    • Beckman Coulter, Inc. (USA)
    • BG Medicine, Inc. (USA)
    • BioForce Nanosciences, Inc. (USA)
    • BioMarker Pharmaceuticals, Inc. (USA)
    • Bristol Myers Squibb Co. (USA)
    • Bruker Daltonics, Inc. (USA)
    • Calibrant Biosystems, Inc. (USA)
    • Caprion Pharmaceuticals, Inc. (Canada)
    • Celera Genomics Group (USA)
    • Correlogic Systems, Inc. (USA)
    • Eli Lilly and Co. (USA)
    • Fujirebio Diagnostics, Inc. (USA)
    • Gene Logic, Inc. (Ore Pharmaceuticals, Inc.) (USA)
    • GeneGo, Inc. (USA)
    • GeneNews Ltd. (Canada)
    • IBEX Technologies, Inc. (Canada)
    • Iconix Biosciences, Inc. (USA)
    • Large Scale Biology Corporation (USA)
    • Metabolon, Inc. (USA)
    • Monogram Biosciences, Inc. (USA)
    • Pathwork Diagnostics (USA)
    • PerkinElmer, Inc. (USA)
    • Pfizer, Inc. (USA)
    • SomaLogic, Inc. (USA)
    • Thermo Fisher Scientific, Inc. (USA)
    • Upstream Biosciences, Inc. (Canada)
    • Vermillion, Inc. (formerly Ciphergen Biosystems) (USA)
  • Therapeutic Area Analysis by Geographic Region
    • Oncology
      • Exhibit 25: Biomarkers in Oncology (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 26: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada (Graphical Representation Included)
    • Cardiology
      • Exhibit 27: Biomarkers in Cardiology (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 28: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada (Graphical Representation Included)
    • Neurology
      • Exhibit 29: Biomarkers in Neurology (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 30: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada
    • Other(Graphical Representation Included)
      • Exhibit 31: Biomarkers in Other Therapeutics (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 32: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada (Graphical Representation Included)
  • Biomarker Discovery Technology Analysis by Geographic Region
    • Imaging
      • Exhibit 33: Imaging Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 34: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada (Graphical Representation Included)
    • Genomics
      • Exhibit 35: Genomic Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 36: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada (Graphical Representation Included)
    • Proteomics
      • Exhibit 37: Proteomic Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 38: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)
    • Metabolomics
      • Exhibit 39: Metabolomic Technologies for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 40: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)
    • Bioinformatics
      • Exhibit 41: Bioinformatics for Biomarker Discovery (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 42: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)
    • Other
      • Exhibit 43: Other Biomarker Discovery Technologies (2005-2012) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 44: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada(Graphical Representation Included)
  • Europe
    • Exhibit 45: Biomarkers (2005-2012) - European Analysis (Current & Future) in US$ Million (Graphical Representation Included)
    • Major Companies in Europe
      • ACE BioSciences A/S (Denmark)
      • Affibody AB (Sweden)
      • Alphalyse A/S (Denmark)
      • Bayer AG (Germany)
      • Biacore International AB (Sweden)
      • BioSense Laboratories AS (Norway)
      • Biotrin International (Ireland)
      • BRAHMS AG (Germany)
      • Dako A/S (Denmark)
      • DxS Ltd. (UK)
      • Epigenomics AG (Germany)
      • GE Healthcare (UK)
      • Genedata AG (Switzerland)
      • GlaxoSmithKline Plc (UK)
      • MDS Pharma Services (UK)
      • Nonlinear Dynamics Ltd. (UK)
      • Novartis AG (Switzerland)
      • Oy Jurilab Ltd. (Finland)
      • Proteome Sciences plc (UK)
      • TheRyte Ltd. (UK)
  • Therapeutic Area Analysis by Geographic Region
    • Oncology
      • Exhibit 46: Biomarkers in Oncology (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 47: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Cardiology
      • Exhibit 48: Biomarkers in Cardiology (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 49: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Neurology
      • Exhibit 50: Biomarkers in Neurology (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 51: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Other
      • Exhibit 52: Biomarkers in Other Therapeutics (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 53: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
  • Biomarker Discovery Technology Analysis by Geographic Region
    • Imaging
      • Exhibit 54: Imaging Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 55: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Genomics
      • Exhibit 56: Genomic Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 57: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Proteomics
      • Exhibit 58: Proteomic Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 59: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Metabolomics
      • Exhibit 60: Metabolomic Technologies for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 61: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Bioinformatics
      • Exhibit 62: Bioinformatics for Biomarker Discovery (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 63: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Other
      • Exhibit 64: Other Biomarker Discovery Technologies (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 65: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
  • Asia-Pacific
    • Exhibit 66: Biomarkers (2005-2012) -Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
    • Major Companies in Asia-Pacific
      • Human Metabolome Technologies, Inc. (Japan)
      • Proteome Systems Ltd. (Australia)
      • Soiken, Inc. (Japan)
      • Triesta Sciences, Inc. (India)
  • Therapeutic Area Analysis by Geographic Region
    • Oncology
      • Exhibit 67: Biomarkers in Oncology (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 68: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific (Graphical Representation Included)
    • Cardiology
      • Exhibit 69: Biomarkers in Cardiology (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 70: Biomarkers in Cardiology (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
    • Neurology
      • Exhibit 71: Biomarkers in Neurology (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 72: Biomarkers in Neurology (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific (Graphical Representation Included)
    • Other
      • Exhibit 73: Biomarkers in Other Therapeutics (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 74: Biomarkers in Other Therapeutics (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
    • Biomarker Discovery Technology Analysis by Geographic Region
      • Imaging
        • Exhibit 75: Imaging Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 76: Imaging Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Genomics
        • Exhibit 77: Genomic Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 78: Genomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Proteomics
        • Exhibit 79: Proteomic Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 80: Proteomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Metabolomics
        • Exhibit 81: Metabolomic Technologies for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 82: Metabolomic Technologies for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Bioinformatics
        • Exhibit 83: Bioinformatics for Biomarker Discovery (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 84: Bioinformatics for Biomarker Discovery (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Other
        • Exhibit 85: Other Biomarker Discovery Technologies (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 86: Other Biomarker Discovery Technologies (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
  • Rest of World
    • Exhibit 87: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
    • Compugen Ltd. (Israel) - A Major Player

III. PRODUCT/TECHNOLOGY RESEARCH

• 1. Introduction
  • Biomarkers Growth Trends - Global Markets
    • Exhibit 88: Global Market for Biomarkers: Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  • Biomarker Groups
    • Biomarkers of Exposure
    • Therapeutic Biomarkers
  • Post Genomic Biomarker-Based Products Market
    • Exhibit 89: Post Genomic Biomarker Based Products Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)
  • Laboratory Process of Biomarkers Development
    • F2-Isoprostances
    • Reactive Oxygen and Nitrogen Species
    • Biomarkers Associated with Breath Exhaled
  • Application of Biomarkers
    • Medical Sector
    • Non-Medical Sector
  • Categorization of Biomarkers
    • DNA Biomarkers
      • Mitochondrial DNA
      • Inheritance of Mitochondria in Living Organisms
      • Mitochondrion Transformations Lead to Cancer
    • RNA Biomarkers
      • Micro RNAs
    • Gene Biomarkers
    • Metabolic Biomarkers
    • Examining Degradation of Anerobic Hydrocarbon with Metabolic Biomarkers
  • Cell Biomarkers
    • Global Market for Cell Based Therapeutics
      • Exhibit 90: Cell Based Therapeutics Market (2005-2012) - Global Market Analysis (Current & Future) by Therapeutic Area for Central Nervous System (CNS), Cancer Other in US$ Million (Graphical Representation Included)
      • Exhibit 91: Cell Based Therapeutics Market (2005-2012) - Percentage Breakdown of Global Market Value by Therapeutic Area for Central Nervous System (CNS), Cancer Other in US$ Million
    • Single Nucleotide Polymorphism (SNP)
    • Protein Biomarkers
      • Upgrade of Proteins for Biomarkers
      • Protein Biomarkers with Array Technologies
      • Proteomic Studies to Enhance Drug Development Process
  • Biomarkers and Molecular Diagnostics
  • Systems Biology
    • Aim of Systems Biology
    • Omics Technologies based Systems Biology
• 2. Various Diseases - Role of Biomarkers
  • Growth Trends - Global Biomarker Therapeutic Areas
    • Exhibit 92: Global Market for Biomarkers: Major Biomarker Therapeutic Areas (Cardiology, Neurology and Oncology) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  • Oncology
    • Growth Trends - Global Market for Biomarkers in Oncology Therapeutics
      • Exhibit 93: Global Market for Biomarkers in Oncology Therapeutics: Geographic Regions (Asia- Pacific, Europe, Japan, Canada, United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
    • Application of biomarkers in Cancer Treatment
    • Cancer Biomarkers
      • Serum Biomarkers
      • Prostate-Specific Antigen
      • Other serum biomarkers
    • Lung Cancer and Biomarkers
      • Features of Biomarkers for Lung Cancer
    • Breast and Ovarian Cancer
    • Colorectal Cancer
      • Hereditary Nonpolyposis Colorectal Cancer
    • Mass Spectrometry - An Emerging Tool for Cancer Biomarker Discovery
      • Role of Chromatography & Mass Spectrometry in Cancer Treatment
      • Mass Spectrometry to Aid Laboratory Methods
      • Global Marker for Mass Spectrometry
        • Exhibit 94: Mass Spectrometry Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)
  • Cardiology
    • Growth Trends - Global Market for Biomarkers in Cardiology Therapeutics
      • Exhibit 95: Global Market for Biomarkers in Cardiology Therapeutics: Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
    • Cardiac Biomarkers - An Overview
    • Renal Insufficiency-Risk of Cardiovascular Disease
    • Global Market for Cardiovascular Diagnostics
      • Exhibit 96: Cardiovascular Diagnostics Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)
  • Neurology
    • Growth Trends - Global Market for Biomarkers in Neurology Therapeutics
      • Exhibit 97: Global Market for Biomarkers in Neurology Therapeutics: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
    • Neurodegenerative Diseases
    • Global Neurodegerative Diseases Market
      • Exhibit 98: Neurodegerative Diseases Market - Global Estimates and Projections for the Period 2005-2012 in US$ Million (Graphical Representation Included)
    • Alzheimer' s
    • Parkinson' s
    • Huntington' s
    • Traumatic Brain Injury
  • Other
    • Biomarkers for Detection of Arthritis
      • Rheumatic Arthritis
    • Biomarkers in Gynecology
      • Pre-Eclampsia in Women
        • Protein Biomarker to Understand the Condition of Pre-Eclampsia
        • Pre-Eclampsia' s and Oxidative Stress
      • Role of Biomarkers of Oxidative Stress in Intricate Pregnancies
    • Premenstrual Dysphoric Disorder
      • Analysis of Premenstrual Dysphoric Disorder
      • Premenstrual Syndrome
    • Biomarkers in Analyzing Oxidative Stress
      • Biomarkers to Analyze Oxidative Stress in Lung Disorders
    • Tuberculosis
    • Detection of Pulmonary Tuberculosis by Biomarkers
    • Biomarkers for Detection of SARS Disease
    • Role of Biomarkers in HIV Detection and Analysis
    • Role of Biomarkers in Malaria Treatment
      • Stage I
      • Stage II
      • Stage III or Key Stage
    • Ageing Biomarkers
      • Exhibit 99: Ageing Biomarkers and Their Effect
    • Biomarkers for Detection of Renal Difficulties Leading To Diabetes Mellitus
      • Type 1 diabetes
      • Type -2 diabetes
• 3. Biomarker Identification Technologies
  • Growth Trends - Global Biomarker Therapeutic Areas
    • Exhibit 100: Global Market for Biomarkers: Major Biomarker Discovery Technologies (Bioinformatics, Genomics, Metabolomics, Proteomics and Imaging) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  • Imaging Technologies
    • Imaging in Preclinical Studies
    • Imaging Clinical Trials-Cancer
    • Growth Trends - Global Imaging Technologies Market for Biomarkers Discovery
      • Exhibit 101: Global Market for Imaging Technologies for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
    • Major Imaging Technologies
      • Computer Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
        • Diffusion MRI techniques
        • Ultrasound or Sonography using MRI
        • Magnetic Resonance Angiography (MRA)
        • Magnetic Resonance Spectroscopy (MRS)
        • Positron Emission Tomography (PET)
          • Method of Usage
  • Genomics
    • Growth Trends - Global Genomics Market for Biomarkers Discovery
      • Exhibit 102: Global Genomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  • Proteomics
    • Growth Trends - Global Proteomics Market for Biomarkers Discovery
      • Exhibit 103: Global Proteomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
    • The Key Technologies that are used for Proteomics
    • Matrix Assisted Laser Desorption Ionization (MALDI)
  • Metabolomics
    • Growth Trends - Global Metabolomics Market for Biomarkers Discovery
      • Exhibit 104: Global Metabolomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
    • The Crucial Role of Metabolomics in Discovery
    • Biomarkers Discovery and Validation through Urinary Proteomics
      • Urinary Exosomes
  • Bioinformatics
    • Growth Trends - Global Bioinformatics Market for Biomarkers Discovery
      • Exhibit 105: Global Bioinformatics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
  • Other
    • Fluorescent Indicators for Cancer Biomarkers and Neutral Sugars
    • Identification of Biomarkers by Feature Wrappers
    • Nanobiotechnology
      • Biomarkers and Nanoproteins
• 4. Biomarkers in Drug Discovery/Development
  • Biomarkers Application in Pharma Industry
    • Nuclear Magnetic Resonance Techniques
    • Mass Spectrometry Techniques to Aid the Study of Proteomics
      • Top Down
      • Bottoms Up
    • Genomics Techniques
    • Metabolomics Techniques
    • Devising and Monitoring of Biological Structure
    • Devising of Sensors
    • Data Base Management and Visualization Tools for Bioinformatics
    • Inhalation Toxicology Techniques
    • Varieties of Micro Arrays Employed in Pharmaceutical Sectors
    • Eco Toxicology Techniques
  • Why Pharma/Biotech Industry is Keen in Biomarkers?
  • Application and Benefits of Biomarkers in Drug Development
  • Verification of Biomarkers Applicability
  • Biomarkers Application in Clinical Drug Development
  • Biomarkers Effect on Discovery and Application of a Drug
  • Drug Safety and Role of Biomarkers
    • Toxic Biomarkers to Aid Drug Manufacture
    • Toxicoproteomics
    • PK/PD Biomarkers in Drug Development
• 5. Product Trends
  • Enhanced Treatment for Spondylarthritis with Innovative Biomarkers
  • A New Diagnostic Marker to Measure Efficiency of Cancer Drug
  • SINE RNA to Emerge as Biomarker for Tobacco Hazards
  • Kinetic Biomarker Enhances Drug Development
  • New Biomarkers to Detect Nephrotoxicity
  • Biomarkers in Combination with Pharmacogenomics

IV. MARKET DYNAMICS

• 1. Market Overview
  • Global Market Analysis
    • Exhibit 106: Biomarkers (2005-2012) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
    • Exhibit 107: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
• 2. Market Trends
  • Biomarkers - An Emerging Trend in Pharma Industry
  • Innovative Biomarker Discovery Methods Aid in Drug Development Stages
  • Biomarkers Becoming Important in Developing Better Drugs
  • Pharma Companies Investing Huge Amounts in Biomarkers Discovery
  • What Pharma Companies Looking in Biomarkers?
• 3. Major Companies in Biomarker Industry
  • Affibody AB (Sweden)
  • Affymetrix, Inc. (USA)
  • Agilent Technologies, Inc. (USA)
  • Applied Biosystems Group (USA)
  • AVIVA Biosciences Corporation (USA)
  • Bayer AG (Germany)
  • Beckman Coulter, Inc. (USA)
  • BG Medicine, Inc. (USA)
  • Biacore International AB (Sweden)
  • BioForce Nanosciences, Inc. (USA)
  • BioMarker Pharmaceuticals, Inc. (USA)
  • BioSense Laboratories AS (Norway)
  • Biotrin International (Ireland)
  • BRAHMS AG (Germany)
  • Bristol Myers Squibb Co. (USA)
  • Bruker Daltonics, Inc. (USA)
  • Calibrant Biosystems, Inc. (USA)
  • Caprion Pharmaceuticals, Inc. (Canada)
  • Celera Genomics Group (USA)
  • Compugen Ltd. (Israel)
  • Correlogic Systems, Inc. (USA)
  • Dako A/S (Denmark)
  • Diagnostics Products Corporation (USA)
  • DxS Ltd. (UK)
  • Eli Lilly and Co. (USA)
  • Epigenomics AG (Germany)
  • Fujirebio Diagnostics, Inc. (USA)
  • GE Healthcare (UK)
  • Gene Logic, Inc. (Ore Pharmaceuticals, Inc.) (USA)
  • Genedata AG (Switzerland)
  • Genego, Inc. (USA)
  • GeneNews Ltd. (Canada)
  • Human Metabolome Technologies, Inc. (Japan)
  • IBEX Technologies, Inc. (Canada)
  • Iconix Biosciences, Inc. (USA)
  • Large Scale Biology Corporation (USA)
  • MDS Pharma Services (UK)
  • Metabolon, Inc. (USA)
  • Monogram Biosciences, Inc. (USA)
  • Nonlinear Dynamics Ltd. (UK)
  • Novartis AG (Switzerland)
  • Oy Jurilab Ltd. (Finland)
  • Pathwork Diagnostics (USA)
  • PerkinElmer, Inc. (USA)
  • Pfizer, Inc. (USA)
  • Proteome Sciences plc (UK)
  • Proteome Systems Ltd. (Australia)
  • Soiken, Inc. (Japan)
  • SomaLogic, Inc. (USA)
  • Thermo Fisher Scientific, Inc. (USA)
  • TheRyte Ltd. (UK)
  • Triesta Sciences, Inc. (India)
  • Upstream Biosciences, Inc. (Canada)
  • Vermillion, Inc. (formerly Ciphergen Biosystems) (USA)
• 4. Major Activities in Biomarker Industry
  • GlaxoSmithKline Biologicals and OncoMethylome Sciences Collaborate for Developing Personalized Cancer Treatment
  • Biomarker Discovered by Korean Researchers to Help in Early Detection of Cancer
  • Singulex' s Biomarker Detection System used in Wyeth' s Research
  • Proteome Sciences Introduces Tandem Mass Tag that Helps Overcome Biomarker Validation Bottleneck
  • Celera and Ipsen Enter Research Collaboration Agreement to Develop Pharmacogenomic Tests
  • Genedata Signs Japanese Research Initiative to Study Metastatic Biomarkers
  • Upstream Biosciences Introduces New Cheminformatics Program to Develop New Drug Discovery Capabilities
  • Banyan Biomarkers Starts International Clinical Trials for Detecting Traumatic Brain Injury with Biomarkers
  • Marshfield Clinic' s Warfarin Biomarker Licensed to Osmetech
  • Siemens Medical Solutions Diagnostics and B·R·A·H·M·S Agree to Develop Procalcitonin (PCT) Assay on Siemens Immunoassay Platforms
  • Fujirebio Diagnostics Granted Patent for Ovarian Cancer Biomarker
  • Gene Logic Adopts New Corporate Identity
  • Celera Completes Acquisition of Atria Genetics, Inc.
  • Olink Bioscience and Applied Biosystems to Collaborate for Commercializing Biomarker Validation Technology
  • Strategic Alliance between GE Global Research, GE Healthcare and Eli Lilly to Develop Molecular In-Vitro Diagnostics for Cancer Therapy
  • BG Medicine Collaborates with Spinal Muscular Atrophy Foundation
  • Vermillion (formerly Ciphergen) Publishes Protein Biomarker Research for PAD
  • Upstream Biosciences Acquires Pacific Pharma Technologies Inc.
  • Ciphergen Adopts New Corporate Identity
  • Upstream Biosciences Signs Agreement with Analytical Biological Services to Provide Tissue Samples for Biomarker Validation
  • Genedata Signs Agreement with Fiehn Laboratory for Refiner MS and Analyst Software
  • Proteome Systems Signs Agreement with BD to Develop Tuberculosis Diagnostics
  • New Collaboration between Partners HealthCare and Affymetrix for Developing Personalized Medicine at a Faster Pace
  • Upstream Biosciences Signs Agreement with Genpathway to Further Biomarker Validation Studies
  • Millipore Acquires Serologicals
  • Dade Behring Receives Sublicense for using Beckman Counter' s New Cardiac Biomarkers
  • Monarch Lifesciences Enters into an Agreement with Genego to Provide Pathway Analysis Services using 1-2-3 Workflow
  • TIBCO Completes Acquisition of Spotfire
  • Monarch LifeSciences™, the New Identity for INCAPS
  • Roche Closes BioVeris Acquisition
  • BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart Failure from ACS Biomarker
  • BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration
  • BG Medicine Forms Research Collaboration with M. D. Anderson Cancer Center
  • Carestream Health Launched (Kodak Health Renamed as Carestream Health)
  • New Collaboration Agreement between Affymetrix Clinical Services Lab, Agencourt, and NuGEN Technologies for Blood Sample Expression Profiling with GeneChip(R) Microarrays
  • Boehringer Ingelheim Expands License with GeneGo to Global Scale
  • Upstream Biosciences Inc. Signs Agreement with NimbleGen Systems Inc. for Biomarker Validation Studies
  • Compugen Enters into Second Diagnostic Agreement with Biosite
  • Lipomics and Agilent Technologies Collaborate on Research and Development of Diagnostic Biomarker Assays
  • Compugen to Collaborate with Teva for Discovery of Novel Biomarkers for Drug Toxicity
  • Illumina Acquires Complete Stake in Solexa
  • BG Medicine and Applied Biosystems to Collaborate on Molecular Medicine Research
  • Epigenomics AG Joins Hands with Centocor Inc. to Discover Biomarkers
  • Siemens Medical Solutions Acquires Bayer' s Healthcare Diagnostic Division
  • BD Acquires TriPath
  • Genetix Acquires Applied Imaging Corp
  • Bruker Daltonics Expands Biomarker Discovery Collaboration with HealthLinx
  • Rules-Based Medicine Merges with Multiplex Biosciences
  • Bio-Rad Acquires Ciphergen' s Life Science Business
  • Caprion Pharmaceuticals and Vertex Pharmaceuticals Expand Biomarker Discovery Collaboration
  • Iconix Changes Corporate Identity
  • Lumera Extends Collaboration with Institute for Systems Biology
  • Tandem Labs Takes Over PharmaKD
  • Axela Collaborates with Abnova to Develop Biomarker Panels
  • Genstruct Extends Agreement GlaxoSmithKline
  • Epigenomics AG Signs R&D Agreement with Johnson & Johnson
  • Siemens Acquires Diagnostic Products Corp
  • PerkinElmer and University of Leicester Sign Research Agreement
  • Asterand Enters into Partnership with Rubicon
  • Applied Biosystems Collaborates with SAIC-Frederick
  • PPD Signs Agreement with PDL BioPharma
  • ART Acquires Alerion Biomedical
  • Varian Acquires IonSpec Corp.
  • BD Takes Over GeneOhm
  • Cytomyx Partners with OrigGene
  • Merck Signs Agreement with FoxHollow Technologies
  • Wyeth Expands Collaboration with Caprion
  • Compugen Enters into Collaboration with Ortho-Clinical Diagnostics
  • BioSystems International Signs Agreement with Euroscreen
  • PPD Takes Over SurroMed
• 5. Major Product Innovations/Launches in Biomarker Industry
  • BioServe Introduces ControlMATCH for Improving Biomarker Validation
  • Metabolon Launches New mVision™ for Biomarker Discovery
  • New Human-14 Protein Removal System Introduced by Agilent Technologies
  • New Tools for Biomarker Research from Applied Biosystems and MDS' Sciex
  • PerkinElmer Introduces New Assay Development Service for Homogenous ELISA Conversions
  • Genedata Launches New Expressionist for Enhanced Cross-Omics Technology Integration in Biomarker Discovery
  • Fluidigm Launches Biomark™ System
  • OXIS Launches New Reagents and Antibodies
  • OGeS and Oxford University Develop Novel Biomarkers
  • ART Launches Fenestra™
  • Agilent Launches Liquid Chromatography (LC) Column
  • Bruker Daltonics Launches Molecular Imager
  • Waters Enhances ProteinLynx
  • Beckman Coulter Upgrades ProteomeLab™
  • GeneData Launches Expressionist® Pro 3.0
  • GenoLogics Enhances ProteusLIMS™
  • Nonlinear Launches Progenesis PG600
  • Bruker Daltonics Upgrades ClinProt™
  • PekinElmer Launches BioXPRESSION™
  • BioGenex Unveils Xmatrx
  • Waters Introduces MassTrak Clinical Solutions
  • Bruker Daltonics Launches Clinical Proteomics System
  • Fujirebio Diagnostics Introduces Blood Test for Mesothelioma
• 6. Regional Market Analysis
  • A. The United States
    • Market Analysis
      • Exhibit 108: Biomarkers (2005-2012) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Exhibit 109: List of Major Companies in the United States
    • Analysis by Therapeutic Area
      • Exhibit 110: Biomarkers (2005-2012) - United States Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 111: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 112: Biomarkers (2005-2012) - United States Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 113: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United States Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B. Europe
    • Market Analysis
      • Exhibit 114: Biomarkers (2005-2012) - European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Exhibit 115: List of Major Companies in Europe
    • Analysis by Geographic Region
      • Exhibit 116: Biomarkers (2005-2012) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 117: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
    • Analysis by Therapeutic Area
      • Exhibit 118: Biomarkers (2005-2012) - European Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 119: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 120: Biomarkers (2005-2012) - European Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 121: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • European Biomarkers Market By Country
  • B1. Germany
    • German Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 122: Biomarkers (2005-2012) - German Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 123: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 124: Biomarkers (2005-2012) - German Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 125: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of German Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B2.The United Kingdom
    • UK Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 126: Biomarkers (2005-2012) - United Kingdom Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 127: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 128: Biomarkers (2005-2012) - United Kingdom Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 129: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of United Kingdom Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B3. Italy
    • Italian Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 130: Biomarkers (2005-2012) - Italian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 131: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Italian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 132: Biomarkers (2005-2012) - Italian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 133: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Italian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B4. France
    • French Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 134: Biomarkers (2005-2012) - French Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 135: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 136: Biomarkers (2005-2012) - French Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 137: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of French Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B5. Spain
    • Spanish Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 138: Biomarkers (2005-2012) - Spanish Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 139: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Spanish Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 140: Biomarkers (2005-2012) - Spanish Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other (Graphical Representation Included)
      • Exhibit 141: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Spanish Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B6. Switzerland
    • Swiss Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 142: Biomarkers (2005-2012) - Swiss Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 143: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swiss Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 144: Biomarkers (2005-2012) - Swiss Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 145: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swiss Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B7. Belgium
    • Belgian Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 146: Biomarkers (2005-2012) - Belgian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 147: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 148: Biomarkers (2005-2012) - Belgian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 149: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Belgian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B8. Sweden
    • Swedish Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 150: Biomarkers (2005-2012) - Swedish Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 151: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swedish Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 152: Biomarkers (2005-2012) - Swedish Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 153: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Swedish Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • B9. Rest of Europe
    • Rest of Europe Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 154: Biomarkers (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 155: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 156: Biomarkers (2005-2012) - Rest of Europe Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 157: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Europe Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • C. Japan
    • Market Analysis
      • Exhibit 158: Biomarkers (2005-2012) - Japanese Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Exhibit 159: List of Major Companies in Japan
    • Analysis by Therapeutic Area
      • Exhibit 160: Biomarkers (2005-2012) - Japanese Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 161: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other (Graphical Representation Included)
    • Analysis by Biomarker Discovery Technology
      • Exhibit 162: Biomarkers (2005-2012) - Japanese Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 163: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Japanese Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • D. Asia-Pacific
    • Market Analysis
      • Exhibit 164: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Exhibit 165: List of Major Companies in Asia-Pacific
    • Analysis by Geographic Region
      • Exhibit 166: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 167: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific (Graphical Representation Included)
    • Analysis by Therapeutic Area
      • Exhibit 168: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 169: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 170: Biomarkers (2005-2012) - Asia-Pacific Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 171: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
    • Asia-Pacific Biomarkers Market By Country
  • D1. China
    • Chinese Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 172: Biomarkers (2005-2012) - Chinese Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 173: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Chinese Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 174: Biomarkers (2005-2012) - Chinese Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 175: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Chinese Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
    • D2. India
    • Indian Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 176: Biomarkers (2005-2012) - Indian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 177: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Indian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 178: Biomarkers (2005-2012) - Indian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 179: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Indian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • D3. Australia
    • Australian Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 180: Biomarkers (2005-2012) - Australian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 181: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 182: Biomarkers (2005-2012) - Australian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 183: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Australian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics
  • D4. Rest of Asia-Pacific
    • Rest of Asia-Pacific Market Analysis
    • Analysis by Therapeutic Area
      • Exhibit 184: Biomarkers (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 185: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 186: Biomarkers (2005-2012) - Rest of Asia-Pacific Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 187: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • E. Canada
    • Market Analysis
      • Exhibit 188: Biomarkers (2005-2012) - Canadian Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Exhibit 189: List of Major Companies in Canada
    • Analysis by Therapeutic Area
      • Exhibit 190: Biomarkers (2005-2012) - Canadian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 191: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Canadian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other(Graphical Representation Included)
    • Analysis by Biomarker Discovery Technology
      • Exhibit 192: Biomarkers (2005-2012) - Canadian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 193: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Canadian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
  • F. Rest of World
    • Market Analysis
      • Exhibit 194: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Exhibit 195: List of Major Companies in Rest of World
    • Analysis by Therapeutic Area
      • Exhibit 196: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
      • Exhibit 197: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of World Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
    • Analysis by Biomarker Discovery Technology
      • Exhibit 198: Biomarkers (2005-2012) - Rest of World Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
      • Exhibit 199: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown of Rest of World Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics Bioinformatics and Other
• 7. Biomarkers - The Industry Outlook

V. CORPORATE DIRECTORY